Glossary
- Abnormal cell growth
- ADC (antibody-drug conjugate)
- Adenosquamous carcinoma
- Adjuvant
- Advanced
- Advanced breast cancer
- Advanced HER2-positive breast cancer
- Advanced NSCLC
- ALK
- ALK+
- Anaemia
- Anaplastic lymphoma kinase positive (ALK+)
- Antibody-drug conjugate
- Antigen
- Antigens
- Avastin
- B cells
- Basal cell carcinoma
- Bone marrow
- BRAF
- Carcinoma
- Chemotherapy
- Chronic lymphocytic leukaemia
- Clinical trial/study
- CLL
- CNS
- Complete remission
- Complete response
- Cost Share Programme
- CRC
- Cytotoxic
- DLBCL
- DNA
- Early HER2-positive breast cancer
- EGFR
- ES-SCLC
- Extensive-stage
- FL
- Follicular lymphoma
- Funded treatment
- GBM
- HER2
- HER2-positive breast cancer
- Hodgkin's lymphoma
- Immune system
- Immunotherapy
- Indolent
- Induction treatment
- iNHL
- Intravenous infusion
- Large cell carcinoma
- Lymph nodes
- Lymph system
- Lymphatic system
- Lymphocyte
- Lymphocytes
- Maintenance therapy
- Malignant
- Medsafe
- Melanoma
- Mesothelioma
- Metastatic NSCLC
- Metastatic
- Monoclonal antibodies
- Monoclonal antibody
- Neoadjuvant
- Non-Hodgkin’s lymphoma
- Non-PHARMAC funded medicines
- Non-squamous cell carcinoma (also called adenocarcinoma)
- NSCLC
- OS
- Overall Survival
- Partial remission
- Partial response
- Pathological complete response (pCR)
- Pathologist
- PD-L1
- PHARMAC
- Platelets
- Progression
- Progression-free survival
- Proteins
- Radiotherapy (sometimes called ‘radiation therapy’)
- Red blood cells
- Refractory
- Registration
- Remission
- Response rate
- Sarcoma
- Sarcomatoid carcinoma
- Small-cell lung cancer (SCLC)
- Spleen
- Squamous cell carcinoma
- Subcutaneous
- Subcutaneous injection
- Targeted therapies
- Tissue biopsy
- TNBC
- Triple negative breast cancer
- Unfunded treatment
- Unresectable cancer
- White blood cells